Christopher G. Chute, M.D., Dr. P.H.
Mayo Clinic, Rochester, Minn. |
PGRN Ontology Network Resource (PHONT)  |
David A. Flockhart, M.D., Ph.D.
Indiana University, School of Medicine |
Consortium on Breast Cancer Pharmacogenomics (COBRA) |
Kathleen M. Giacomini, Ph.D.
University of California, San Francisco |
Pharmacogenetics of Membrane Transporters (PMT) |
Kathleen M. Giacomini, Ph.D.
University of California, San Francisco |
Pharmacogenomics Research Network III and RIKEN Center for Genomic Medicine Alliance (PGRN-CGM) |
Richard A. Gibbs, Ph.D.
Baylor College of Medicine, Houston |
Next Gen Sequencing-Baylor/Mayo (BCM-HGSC) |
Julie A. Johnson, Pharm.D. and Rhonda Cooper-DeHoff, Pharm.D.
University of Florida, Gainesville |
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) |
John Kelsoe, M.D.
University of California, San Diego |
Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) |
Ronald M. Krauss, M.D.
Children's Hospital Oakland Research Institute, California |
Pharmacogenomics and Risk of Cardiovascular Disease (PARC) |
| Caryn Lerman, Ph.D., University of Pennsylvania, Philadelphia and Rachel F. Tyndale, Ph.D., University of Toronto |
Pharmacogenetics of Nicotine Addiction Treatment (PNAT) |
Julio Licinio, M.D.
University of Miami, Miller School of Medicine |
University of Miami Pharmacogenetics and Pharmacogenomics Research Group (PPRG) |
Elaine R. Mardis, Ph.D.
The Genome Center, Washington University School of Medicine |
Pharmacogenomics Research Network - Next Generation Sequencing (WU-NGS) |
Howard L. McLeod, Pharm.D.
University of North Carolina at Chapel Hill |
Functional Polymorphism Analysis in Drug Pathways (CREATE) |
Prakash M. Nadkarni, M.D.
Yale University, New Haven, Connecticut |
Design and Implementation of Pharmacogenetic Network (DIPN) |
|
Deborah A. Nickerson, Ph.D.
University of Washington School of Medicine, Seattle |
PGRN Network Resource: Next Generation Sequencing (UW-NEXTGEN) |
Daniel T. O'Connor, M.D.
University of California, San Diego |
Autonomic Pharmacodynamic Pharmacogenomics |
Soumya Raychaudhuri, M.D., Ph.D. and Michael Brenner, M.D.
Brigham and Women's Hospital, Boston |
Pharmacogenomics of Rheumatoid Arthritis Therapy (PhRAT) |
Mark J. Ratain, M.D., Nancy J. Cox, Ph.D. and M. Eileen Dolan, Ph.D.
University of Chicago |
Pharmacogenetics of Anticancer Agents (PAAR) |
Mary V. Relling, Pharm.D.
St. Jude Children's Research Hospital, Memphis, Tennessee |
Pharmacogenomics of Anticancer Agents Research in Children (PAAR4Kids) |
Marylyn D. Ritchie, Ph.D.
Vanderbilt University, Nashville, Tennessee |
PGRN Statistical Analysis Resource (P-STAR) |
Dan M. Roden, M.D.
Vanderbilt University, Nashville, Tennessee |
PharmacoGenomic discovery and replication in very large patient POPulations (PG-POP) |
Dan M. Roden, M.D.
Vanderbilt University Medical Center, Nashville, Tennessee |
Pharmacogenomics of Arrhythmia Therapy (PAT) |
Mark A. Rothstein, J.D.
University of Louisville, Kentucky |
Pharmacogenomics & Minority Populations (PMP) |
Wolfgang Sadee, Dr.rer.nat., M. Pharmacy
The Ohio State University, Columbus |
Expression Genetics in Drug Therapy (XGEN) |
Alan R. Shuldiner, M.D.
University of Maryland School of Medicine, Baltimore |
The Amish Pharmacogenomics of Anti-Platelet Intervention Study (PAPI) |
Kenneth E. Thummel, Ph.D. and Wylie Burke, M.D., Ph.D.
University of Washington, Seattle |
Pharmacogenetics in Rural and Underserved Populations (NWAP) |
Richard Weinshilboum, M.D. and Liewei Wang, M.D., Ph.D.
Mayo Clinic, Rochester, Minn. |
Pharmacogenetics of Phase II Drug Metabolizing Enzymes (PPII) |
Scott T. Weiss, M.D., M.S. and Kelan G. Tantisira, M.D., M.P.H.
Brigham and Women's Hospital and Harvard Medical School, Boston |
Pharmacogenetics of Asthma Treatment (PHAT) |